In that the TZD class of PPARγ agonists is associated with adverse cardiovascular events, additional studies on the efficacy of PPARγ agonists and other lead compounds as adjuvant or combination therapy to treat cancer should be designed to look at the cardiovascular risks and benefits in addition to their efficacy in treating the primary disease. Here, PPARG is linked to cancer.